<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01840501</url>
  </required_header>
  <id_info>
    <org_study_id>CR101337</org_study_id>
    <secondary_id>42721458EDI1001</secondary_id>
    <secondary_id>2013-000557-47</secondary_id>
    <nct_id>NCT01840501</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single- and Multiple-Doses of JNJ-42721458 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (what the
      body does to the medication), potential immunogenicity (ability to induce an immune
      response), and pharmacodynamics (what the drug does to the body) after administration of
      JNJ-42721458 in healthy adult male participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (the study medication is assigned by chance), double-blind (neither
      physician nor participant knows the identity of the assigned treatment), placebo-controlled
      (an inactive substance that is compared with a medication to test whether the medication has
      a real effect in a clinical study), single-ascending (increasing) dose and multiple-ascending
      dose study of JNJ-42721458 compound in healthy males. The study is divided in two parts. Part
      1 is a single-ascending dose (SAD) study which will include up to 10 panels (using ascending
      doses starting from 0.1 mg) in which a single dose of the study medication will be
      administered on Day 1. Part 2 is a multiple-ascending dose (MAD) study which will include
      approximately 6 panels (using ascending doses starting from 5.0 mg) in which multiple doses
      of study medication will be administered once daily for 10 days.

      Part 2 will be initiated after completion of dosing and all relevant evaluations from Part 1.
      In each panel of Part 1 and 2, 6 participants will be randomly assigned to receive
      JNJ-42721458 and 2 participants randomly assigned to placebo. Safety evaluations will include
      assessment of adverse events, physical examinations, laboratory tests, vital signs,
      electrocardiograms, cardiac telemetry and evaluation of injection sites which will be
      monitored throughout the study. The total study duration for each participant will be
      approximately 6-7 weeks in Part 1 and 7-8 weeks for each participant in Part 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 and 2: Number of participants with adverse events</measure>
    <time_frame>Up to 17 weeks</time_frame>
    <description>Number of participants with adverse events will be used as a measure of safety and tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and 2: Maximum observed concentration (Cmax) of JNJ-42721458</measure>
    <time_frame>Up to Day 10 (for Part 1) and Day 27 (for Part 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and 2: Time to reach the maximum plasma concentration (tmax) of JNJ-42721458</measure>
    <time_frame>Up to Day 10 (for Part 1) and Day 27 (for Part 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and 2: Area under the concentration-time curve of JNJ-42721458, from time 0 to infinity, with extrapolation of the terminal phase</measure>
    <time_frame>Up to Day 10 (for Part 1) and Day 27 (for Part 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and 2: Area under the concentration-time curve of JNJ-42721458 during a dosing interval at steady state</measure>
    <time_frame>Up to Day 10 (for Part 1) and Day 27 (for Part 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and 2: Terminal half-life (t1/2) of JNJ-42721458</measure>
    <time_frame>Up to Day 10 (for Part 1) and Day 27 (for Part 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and 2: Apparent systemic clearance of drug after subcutaneous administration of JNJ-42721458</measure>
    <time_frame>Up to Day 10 (for Part 1) and Day 27 (for Part 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and 2: Apparent volume of distribution after subcutaneous administration of JNJ-42721458</measure>
    <time_frame>Up to Day 10 (for Part 1) and Day 27 (for Part 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and 2: Plasma levels of antibodies to JNJ-42721458 for evaluation of potential immunogenicity</measure>
    <time_frame>Up to Day 10 (for Part 1) and Day 27 (for Part 2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Change from baseline in resting heart rate</measure>
    <time_frame>Up to Day 10 (for Part 1) and Day 27 (for Part 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Change from baseline in resting peripheral blood pressure</measure>
    <time_frame>Up to Day 10 (for Part 1) and Day 27 (for Part 2)</time_frame>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Panel 1 (0.1 mg JNJ-42721458)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive a single dose of 0.1 mg of JNJ-42721458.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Panel 2 (0.3 mg JNJ-42721458)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive a single dose of 0.3 mg of JNJ-42721458.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Panel 3 (1.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive a single dose of 1.0 mg of JNJ-42721458.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Panel 4 (2.5 mg JNJ-42721458)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive a single dose of 2.5 mg of JNJ-42721458.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Panel 5 (5.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive a single dose of 5.0 mg of JNJ-42721458.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Panel 6 (10.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive a single dose of 10.0 mg of JNJ-42721458.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Panel 7 (20.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive a single dose of 20.0 mg of JNJ-42721458.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Panel 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-7 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Panel 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-8 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Panel 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-9 in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 participants from each panel will receive a single dose of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Panel 1 (5.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive multiple doses of 5.0 mg of JNJ-42721458.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Panel 2 (10.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive multiple doses of 10.0 mg of JNJ-42721458.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Panel 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-2 in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Panel 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-3 in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Panel 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-4 in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Panel 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-5 in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 participants from each panel will receive multiple doses of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-42721458 (single dose)</intervention_name>
    <description>JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.</description>
    <arm_group_label>Part 1: Panel 1 (0.1 mg JNJ-42721458)</arm_group_label>
    <arm_group_label>Part 1: Panel 2 (0.3 mg JNJ-42721458)</arm_group_label>
    <arm_group_label>Part 1: Panel 3 (1.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_label>Part 1: Panel 4 (2.5 mg JNJ-42721458)</arm_group_label>
    <arm_group_label>Part 1: Panel 5 (5.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_label>Part 1: Panel 6 (10.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_label>Part 1: Panel 7 (20.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_label>Part 1: Panel 8</arm_group_label>
    <arm_group_label>Part 1: Panel 9</arm_group_label>
    <arm_group_label>Part 1: Panel 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-42721458 (multiple doses)</intervention_name>
    <description>JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.</description>
    <arm_group_label>Part 2: Panel 1 (5.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_label>Part 2: Panel 2 (10.0 mg JNJ-42721458)</arm_group_label>
    <arm_group_label>Part 2: Panel 3</arm_group_label>
    <arm_group_label>Part 2: Panel 4</arm_group_label>
    <arm_group_label>Part 2: Panel 5</arm_group_label>
    <arm_group_label>Part 2: Panel 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (single dose)</intervention_name>
    <description>Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.</description>
    <arm_group_label>Part 1: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (multiple doses)</intervention_name>
    <description>Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.</description>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (weight kg/m2) between 18 and 30 kg/m2, and body weight not less than
             50 kg

          -  Participant is judged to be generally in good health based on medical history,
             physical examination, vital signs and laboratory safety tests

          -  Blood pressure between 90 and 135 mmHg systolic, inclusive, and no higher than 90 mmHg
             diastolic

          -  A 12-lead electrocardiogram consistent with normal cardiac conduction and function

        Exclusion Criteria:

          -  History of or current clinically significant medical illness

          -  Clinically significant abnormal values for hematology, clinical chemistry or
             urinalysis at screening or on Day -1 (at admission to the study center)

          -  Estimated creatinine clearance of less than or equal to 80 mL/min

          -  Clinically significant abnormal physical examination, vital signs or 12 lead
             electrocardiogram at screening or on Day -1

          -  Participant demonstrates orthostatic change in vital signs measurements on screening
             or predose while going from a semi recumbent to standing position

          -  History of significant multiple and/or severe allergies (including latex allergies) or
             known history of clinically significant allergies to polyethylene glycol (PEG)
             containing or other PEGylated products
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>May 5, 2014</last_update_submitted>
  <last_update_submitted_qc>May 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>JNJ-42721458</keyword>
  <keyword>Male</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Immunogenicity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

